AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01920568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid 4 mg
Description: Zoledronic acid 4 mg (or equivalent clearance-adjusted dose in subjects with baseline creatinine clearance \<=60 ml/min) will be diluted in either 0.9% sodium chloride or 5% dextrose injection and administered IV.
Study NCT01920568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo IV
Description: The placebo will consist of 1.7 mL 0.9% w/v sodium chloride
Study NCT01920568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo SC
Description: The placebo will consist of either 0.9% w/v sodium chloride or 5% dextrose injection
Study NCT01920568 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium supplement
Description: Subjects are strongly recommended to take daily supplements of at least 500 mg calcium from the day of consent and until completion of the Week 73 follow-up visit.
Study NCT02775721 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nutritional Therapy Education and Evaluation
Description: Nutritional therapy will be conducted per standard of care, the protocol does not dictate the frequency or treatment plan of care. Nutritional therapy and evaluation is assessed per the attending dietitian. The study team will collect all data related to nutritional therapy education and evaluation at each study visit per protocol. All collected data will be utilized in final protocol analysis.
Study NCT02775721 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Quality of Life Questionnaire C30 version 3
Description: 30-item instrument that measures the Health Related Quality of Life (HRQoL) in a wide range of cancer patient populations.
Study NCT02775721 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Quality of Life Questionnaire EORTC QLO - H&N35
Description: 35-item instrument that measures the Health Related Quality of Life specific to Head and Neck cancer patient populations.
Study NCT02240160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: Oromucosal spray containing THC (27 mg/mL) and CBD (25 mg/mL) in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Each 100 μL spray delivers 2.7 mg THC and 2.5 mg CBD.
Study NCT04054388 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LINE re-education
Study NCT02698475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 0.75 mg/kg
Description: Participants weighing less than (\<) 60 kilograms will receive ustekinumab 0.75 milligram per kilogram (mg/kg) at Weeks 0 and 4 followed by every 12 weeks dosing with the last dose at Week 40. Eligible participants for LTE period will continue to receive ustekinumab 0.75 mg/kg up to Week 248.
Study NCT00754624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere® Insulin Inhalation Powder and MedTone™ Inhaler
Description: Inhalation starting at 15, 30, or 60U doses and can be titrated up or down by 15U to a minimum of 15U or a maximum of 90U
Study NCT03132376 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Water Preload Drink
Description: Participants were given 275 ml (0 kcal) water to consume in the morning following an overnight fast. This served as the control drink.
Study NCT03132376 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein Isolate Drink
Description: Participants were given an isovolumetric (to the water), 160 kcal drink with 30 g whey protein to consume in the morning following an overnight fast.
Study NCT03132376 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micellar Casein Protein Drink
Description: Participants were given an isovolumetric (to the water), 160 kcal drink with 30 g micellar casein to consume in the morning following an overnight fast.
Study NCT03132376 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Egg White Isolate Protein Drink
Description: Participants were given an isovolumetric (to the water), 160 kcal drink with 30 g egg white isolate protein to consume in the morning following an overnight fast.
Study NCT03132376 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Egg White Concentrate Protein Drink
Description: Participants were given an isovolumetric (to the water), 160 kcal drink with 30 g egg white concentrate protein to consume in the morning following an overnight fast.
Study NCT03096210 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Titanium-Prepared Platelet Rich Fibrin
Description: Blood samples were collected from the each participant's arm in the test group by 20 ml syringe and then was transferred into 10ml grade IV titanium tube without anticoagulant. After centrifugation of blood samples (2800 rpm, 12 minutes) at room temperature, the T-PRF clot was removed from the tubes with sterile tweezers. 6 blood tubes were collected for a sinus floor elevation/lifting operation and 6 T-PRFs were prepared for each participant.
Study NCT02698475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Description: Participants weighing greater than or equal to (>=) 60 kg to less than or equal to (\<=) 100 kg will receive ustekinumab 45 mg at Weeks 0 and 4 followed by every 12 weeks dosing with the last dose at Week 40. Eligible participants for LTE period will continue to receive ustekinumab 45 mg up to Week 248.
Study NCT02698475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Description: Participants weighing >100 kg will receive ustekinumab 90 mg at Weeks 0 and 4 followed by every 12 weeks dosing with the last dose at Week 40. Eligible participants for LTE period will continue to receive ustekinumab 90 mg up to Week 248.
Study NCT03096210 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Allograft (CTBA Allograft)
Description: After careful elevation of the schneiderian membrane without perforation, allograft was only used for augmentation of the sinus floor in the control group.
Study NCT01564797 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home Health Party
Description: An education-based lay health educator-led intervention designed to educate Hispanic participants with elevated HA1c levels about diabetes, treatment of diabetes, and diet and lifestyle changes.
Study NCT00418314 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Empiric programming or one-time optimization using a non-IEGM method.
Study NCT00418314 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QuickOpt
Description: Frequent optimization using QuickOpt to optimize AV/PV and VV delays.
Study NCT01920568 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D supplement
Description: Subjects are strongly recommended to take daily supplements of at least 400 IU of vitamin D from the day of consent and until completion of the Week 73 follow-up visit.
Study NCT02687555 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification of Appraisals (CBM-App)
Study NCT02687555 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Peripheral Vision Task (control condition)
Study NCT02694068 — intervention group
Intervention type: OTHER
Intervention: Peritoneal Equilibrium Test
Description: These will be done as part of standard of care procedures. PETs will not be performed solely for research purposes.
Study NCT02694068 — intervention group
Intervention type: OTHER
Intervention: 4 hour dwell of 2.5/4.25% dextrose solution
Description: If a PET is not performed annually as part of standard of care, subjects will undergo a 4 hour timed dwell with either 2.5 or 4.25% dextrose solution. This will be for the purposes of sample collection and/or measurement of ultrafiltration capacity.
Study NCT02940145 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: The investigation was carried out over a period of 16 weeks, with 12 weeks dedicated to the RT program and 4 weeks allocated for measurements. Anthropometric, body composition, and blood samples measurements were performed at weeks 1-2, and 15-16. A supervised progressive RT was performed between weeks 3-14. The CG did not perform any type of physical exercise during this period.
Study NCT02554669 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: postprandial and postabsorptive physical activity on treadmill
Study NCT00894569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel/carboplatin
Description: 6 cycles paclitaxel 175 mg/m² and carboplatin AUC 5, repetition d22.
Study NCT00894569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel/carboplatin
Description: 6 cycles paclitaxel 175 mg/m² and carboplatin AUC 5, repetition d22.
Study NCT00894569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: cetuximab (400 mg/m² first dose, 250 mg/m² weekly) until disease progression
Study NCT03029377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Posture Study, Autonomic Function Tests, and a Stress Test
Description: Participants will undergo a Posture Study, Autonomic Function Tests, and a Stress Test. Participants' blood will be drawn to measure markers of sympathetic nervous system function at baseline, in three postural positions, after autonomic tests, and after a stress test.
Study NCT03029377 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Posture Study, Autonomic Function Tests, and a Stress Test
Description: Participants will undergo a Posture Study, Autonomic Function Tests, and a Stress Test. Participants' blood will be drawn to measure markers of sympathetic nervous system function at baseline, in three postural positions, after autonomic tests, and after a stress test.
Study NCT00099853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: Vildagliptin 50 mg tablets
Study NCT00099853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: pioglitazone 45 mg qd
Study NCT00099853 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pioglitazone
Description: pioglitazone 45 mg qd
Study NCT00099853 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vildagliptin matching placebo
Study NCT00507962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 100 mg/m\^2 Intraarterial On Day 1 Every 4 Weeks
Study NCT00507962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Doxorubicin
Description: Starting dose 20 mg/m\^2 IV On Day 1 Every 4 Weeks
Study NCT01356472 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Imipenem/cilastatin
Description: the intervention group was designed for combined linezolid plus imipenem for treating MRSA VAP
Study NCT01741324 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D 25 microg/d
Description: The vitamin D supplement will be provided as a milk drink taken daily.
Study NCT01741324 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D 10 microg/d
Description: The vitamin D supplement will be provided as a milk drink taken daily.
Study NCT03876184 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aesthetic archwires
Description: During bond-up, randomly allocated envelope will be opened and archwires will be ligated with elastomeric ligatures.After 4 weeks,the same archwires will be retied.Any fractured archwire will be recorded and discarded.The fractured wire will be replaced with conventional archwire and treatment continues.On the 2nd follow-up (at 8th week), the tested wires are collected, disinfected, dried and placed back in the allocated envelope.Upper and lower impressions will be taken.Questionnaires will be answered by participants.The trial ends and treatment continues as planned.Fractured archwire will be recorded and discarded.
Study NCT03876184 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: During bond-up, randomly allocated envelope will be opened and archwires will be ligated with elastomeric ligatures.After 4 weeks,the same archwires will be retied.Any fractured archwire will be recorded and discarded.The fractured wire will be replaced with conventional archwire and treatment continues.On the 2nd follow-up (at 8th week), the tested wires are collected, disinfected, dried and placed back in the allocated envelope.Upper and lower impressions will be taken.This group will not answer the questionnaire.The trial ends and treatment continues as planned.Fractured archwire will be recorded and discarded.
Study NCT01741324 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: No extra vitamin D
Description: Milk drink with no extra vitamin D (placebo)
Study NCT01643252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: riboflavin: 0.12% riboflavin ophthalmic solution with the KXL system
Description: Subjects will receive 0.12% riboflavin ophthalmic solution (VibeX) followed by irradiation with the KXL system at 30mW/cm\^2 for 4 minutes
Study NCT01643252 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo: 0.0% riboflavin ophthalmic solution with the KXL system
Description: Subjects will receive 0.0% riboflavin ophthalmic solution (placebo) followed by irradiation with the KXL system at 30mW/cm\^2 for 4 minutes
Study NCT00904098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Frovatriptan
Description: This study employed a prospective, non-randomized, open-label single-sequence design. The study was conducted in two phases:~1. A Usual Care phase (approximately 1 month in duration) included one menstrual period during which female patients treated all episodes of migraine headaches using their current treatment (referred to as the Baseline phase in the protocol)~2. An Acute Treatment phase (approximately 1 month in duration), following the Usual Care phase, included one menstrual period during which female patients used frovatriptan 2.5 mg to treat all episodes of migraine headache when their headache reached IHS Grade 1. If needed, a second dose of frovatriptan 2.5 mg was administered; however, this second dose could not be administered within 2 hours of the initial dose (i.e., there must have been at least 2 hours between doses of frovatriptan). The total daily dose of frovatriptan was not to exceed 3 tablets over a 24-hour period.
Study NCT00904098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Current treatment used to treat all migraine headaches
Study NCT03745443 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: increase and decrease positive end-expiratory pressure
Description: 20 minutes before the end of anesthesia and surgery PEEP was increased by 2 on every 5 breaths to 11. Ventilation with PEEP 11 was maintained for 2 minutes. Then, PEEP was reduced by 2 on every 5 breaths to 5 cmH2O
Study NCT03836833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC/3TC/LPV/r granules (30/15/40/10 mgs)
Description: This is a fixed dose combination. Each capsule contains Lopinavir (40mg), Ritonavir (10mg), Abacavir (30mg) and Lamivudine (15mg) in granules formulation.~Dosage according to patient's weight:~Between 3 and 5.9kg: 2 capsules twice a day Between 6 and 9.9kg: 3 capsules twice a day Between 10 and 13.9kg: 4 capsules twice a day Between 14 and 19.9kg: 5 capsules twice a day Between 20 and 24.9kg: 6 capsules twice a day
Study NCT03836833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPV/r Pellets (40/10mgs) plus ABC/3TC (60/30mgs)
Description: Lopinavir/Ritonavir (40/10mg pellets) plus dual Abacavir/Lamivudine (60/30mg dispersible tablets)~Dosage according to patient's weight:~LPV/r Pellets:~Between 3 and 5.9kg: 2 capsules twice a day Between 6 and 9.9kg: 3 capsules twice a day Between 10 and 13.9kg: 4 capsules twice a day Between 14 and 19.9kg: 5 capsules twice a day Between 20 and 24.9kg: 6 capsules twice a day~ABC/3TC:~Between 3 and 5.9kg: 1 tablet twice a day Between 6 and 9.9kg: 1.5 tablets twice a day Between 10 and 13.9kg: 2 tablets twice a day Between 14 and 19.9kg: 2.5 tablets twice a day Between 20 and 24.9kg: 3 tablets twice a day
Study NCT03897725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth Coaching
Description: Telehealth coaching to promote adherence
Study NCT02445677 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active transcutaneous electrical nerve stimulation (TENS)
Description: TENS is a technique use to relieve pain in an injured or diseased part of the body in which electrodes applied to the skin deliver intermittent stimulation to surface nerves and block the transmission of pain signals. In this research, the frequency will be set at 100 Hz, implusion duration at 60 μsec and intensity will be increase until having strong but confortable stimulations.
Study NCT02445677 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Simulated transcutaneous electrical nerve stimulation (TENS)
Description: A modification of the TENS connexion parameters will prevent the current from reaching the electrods (once a first sensation will be perceived).
Study NCT00123578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam
Description: Lorazepam
Study NCT00123578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentobarbital
Description: Pentobarbital
Study NCT00856206 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rilonacept
Description: Rilonacept 160 mg subcutaneous injection once a week
Study NCT00856206 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection once a week
Study NCT02950987 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole Body MRI
Study NCT03958721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1,000 mg/m2 twice daily taken by mouth every other week
Study NCT03958721 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Once daily (Monday through Friday) for six weeks
Study NCT00931762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Panobinostat oral capsules
Study NCT03931291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APR-246
Description: APR-246 will be administered on Days 1-4, with azacitidine on Days 1-5, of every 28 day cycle. Patients may receive a maximum of 12 cycles.
Study NCT01579175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chewing gum
Description: Sugar Free (Extra spearment) gum given to chew every 4 hours during waking hours for 15 minutes.
Study NCT02175589 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Colchicine Cessation
Description: Colchicine Cessation
Study NCT01320085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Study NCT04478474 — intervention group
Intervention type: DRUG
Intervention: Ganciclovir
Description: Type of allogeneic transplant, HLA match, graft manipulation, use of ATG and/or Campath, CMV status (donor and recipient), maximal acute GVHD stage and grade, CMV viremia/disease through day +100, days received ganciclovir prophylaxis, adverse events related directly or secondary to ganciclovir prophylaxis.
Study NCT03709771 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ambulatory Blood Pressure Measurement
Description: Baseline: Subjects will undergo an abbreviated physical exam, review changes in medical history since last oncology visit, blood collection, urine collection, blood pressure and heart rate in triplicate, baseline and hyperemic digital velocity time interval (VTI) using pulse amplitude tonometry, cubital vein endothelial cell harvest, and ambulatory 24 blood pressure measurement.~Follow-up Visit (approx 1 month after starting treatment): Review changes in medications and any medical events that happened since the last visit, an abbreviated physical exam, blood collection, urine collection, blood pressure and heart rate in triplicate, baseline and hyperemic velocity time interval (VTI), digital pulse amplitude tonometry, endothelial cell harvest, and ambulatory 24 blood pressure.
Study NCT03980106 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reciprocal Inhibition Muscle Energy Technique
Description: In this technique, the subject will be asked to contract antagonist muscles against a moderate resistant force provided by the therapist to inhibit the contraction of the agonist muscle.
Study NCT03980106 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-Isometric Inhibition Muscle Energy Technique
Description: In this technique, the subject will be asked to contract agonist muscles against a moderate resistant force provided by the therapist to inhibit the contraction of the agonist muscle.
Study NCT01819402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone vs Glimepiride
Study NCT01819402 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Pioglitazone vs Glimepiride
Study NCT03902197 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 hsCAR-T
Description: CD19 hsCAR-T will be administered by I.V. infusion
Study NCT01934530 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Soft Tissue Grafting
Description: All patients were treated with infiltration of local anesthetic with vasoconstrictor if noted tolerable by the medical history. Surgeons were then notified if the patient was randomized to the test or control according to a blinded treatment assignment. In both groups, anesthesia was confirmed at the implant site and the palatal donor site if indicated. The recipient bed was then prepared.~Vertical incisions were made at the defect at line angles and horizontal incisions connected the two vertical releases intrasulcularly without involving the interdental papilla. The flap was reflected as a full thickness flap maintaining the integrity of the collagen attachment with de-epithelialization of papilla to allow for coronal advancement.